These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23826381)

  • 1. Extracellular sphingosine-1-phosphate: a novel actor in human glioblastoma stem cell survival.
    Riccitelli E; Giussani P; Di Vito C; Condomitti G; Tringali C; Caroli M; Galli R; Viani P; Riboni L
    PLoS One; 2013; 8(6):e68229. PubMed ID: 23826381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells.
    Marfia G; Campanella R; Navone SE; Di Vito C; Riccitelli E; Hadi LA; Bornati A; de Rezende G; Giussani P; Tringali C; Viani P; Rampini P; Alessandri G; Parati E; Riboni L
    Glia; 2014 Dec; 62(12):1968-81. PubMed ID: 25042636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Sphingosine-1-Phosphate Downstream of EGFR Increases Human Glioblastoma Cell Survival.
    Bassi R; Brambilla S; Tringali C; Giussani P
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines.
    Oancea-Castillo LR; Klein C; Abdollahi A; Weber KJ; Régnier-Vigouroux A; Dokic I
    Cancer Biol Ther; 2017 Jun; 18(6):400-406. PubMed ID: 28494176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
    Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
    Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells.
    Zhu TZ; Li XM; Luo LH; Song ZQ; Gao X; Li ZQ; Su JY; Liang GB
    Int J Oncol; 2014 Aug; 45(2):699-709. PubMed ID: 24841897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
    Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sphingosine kinase inhibitor combined with temozolomide induces glioblastoma cell death through accumulation of dihydrosphingosine and dihydroceramide, endoplasmic reticulum stress and autophagy.
    Noack J; Choi J; Richter K; Kopp-Schneider A; Régnier-Vigouroux A
    Cell Death Dis; 2014 Sep; 5(9):e1425. PubMed ID: 25255218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy.
    Auffinger B; Tobias AL; Han Y; Lee G; Guo D; Dey M; Lesniak MS; Ahmed AU
    Cell Death Differ; 2014 Jul; 21(7):1119-31. PubMed ID: 24608791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
    Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway.
    Shi L; Fei X; Wang Z; You Y
    In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1047-55. PubMed ID: 26170223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
    Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
    J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.
    Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S
    Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
    Bryan L; Paugh BS; Kapitonov D; Wilczynska KM; Alvarez SM; Singh SK; Milstien S; Spiegel S; Kordula T
    Mol Cancer Res; 2008 Sep; 6(9):1469-77. PubMed ID: 18819934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes.
    Anelli V; Bassi R; Tettamanti G; Viani P; Riboni L
    J Neurochem; 2005 Mar; 92(5):1204-15. PubMed ID: 15715670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma.
    Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M
    Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis.
    Abuhusain HJ; Matin A; Qiao Q; Shen H; Kain N; Day BW; Stringer BW; Daniels B; Laaksonen MA; Teo C; McDonald KL; Don AS
    J Biol Chem; 2013 Dec; 288(52):37355-64. PubMed ID: 24265321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.